申请人:Alnylam Pharmaceuticals, Inc.
公开号:US20130178512A1
公开(公告)日:2013-07-11
The present invention provides iRNA agents comprising at least one subunit of the formula (I):
wherein:
A and B are each independently for each occurrence O, N(R
N
) or S;
X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula (I), —P(Z′)(Z″)— or -Linker-R;
R is L
G
, -Linker-L
G
, or has the structure shown below:
L
G
is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide;
R
N
is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and
Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.